Clinical Trial Update: Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating anti-CD19 CAR-NK cell therapy in relapsed or resistant acute lymphoblastic leukemia. The study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Anti-CD19 CAR-NK cells (Chimeric Antigen Receptor NK cell therapy targeting CD19)

Snippet

Sponsor: Shahid Beheshti University of Medical Sciences | Conditions: Acute Lymphocytic Leukemia in Relapse | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING